BACKGROUND: Guidelines recommend antiretroviral therapy (ART) initiation at CD4 <350 cells per microliter for HIV-infected individuals in resource-limited settings. However, funding for treatment expansion remains uncertain. We forecast the mortality impact of ART expansion alternatives in Haiti. METHODS: We used data from Haiti to develop a country-specific model of HIV disease. The model projects the mortality, total number of HIV-infected individuals, and number and coverage (percentage of those eligible) on ART by simulating cohorts of HIV-infected individuals over 10 years. Five ART expansion scenarios, ranging from fully expanded ART (best case) to No New ART (worst case), were assessed. RESULTS: By 2010, the model predicts 103,500 individuals living with HIV in Haiti, of whom 27,300 were estimated to receive ART. Continuing ART initiation at current rates requires increasing the number on ART to 43,300 by 2020 (56% coverage), with 89,700 deaths estimated between 2010 and 2020. The number on ART could increase by 7400 (+17.1%, best case) or decrease by 25,600 (-59.1%, worst case), resulting in 19,500 deaths averted and 9900 fewer in care awaiting ART (best versus worst case). Results are sensitive to untreated disease progression and pre-ART loss from care. Increased HIV testing, linkage to care, and retention in care can avert additional deaths and achieve nearly 80% ART coverage with optimal policy improvements. CONCLUSIONS: In resource-limited settings, continued improvements in HIV treatment access will save lives. Efforts to efficiently expand ART access should remain a global priority.
BACKGROUND: Guidelines recommend antiretroviral therapy (ART) initiation at CD4 <350 cells per microliter for HIV-infected individuals in resource-limited settings. However, funding for treatment expansion remains uncertain. We forecast the mortality impact of ART expansion alternatives in Haiti. METHODS: We used data from Haiti to develop a country-specific model of HIV disease. The model projects the mortality, total number of HIV-infected individuals, and number and coverage (percentage of those eligible) on ART by simulating cohorts of HIV-infected individuals over 10 years. Five ART expansion scenarios, ranging from fully expanded ART (best case) to No New ART (worst case), were assessed. RESULTS: By 2010, the model predicts 103,500 individuals living with HIV in Haiti, of whom 27,300 were estimated to receive ART. Continuing ART initiation at current rates requires increasing the number on ART to 43,300 by 2020 (56% coverage), with 89,700 deaths estimated between 2010 and 2020. The number on ART could increase by 7400 (+17.1%, best case) or decrease by 25,600 (-59.1%, worst case), resulting in 19,500 deaths averted and 9900 fewer in care awaiting ART (best versus worst case). Results are sensitive to untreated disease progression and pre-ART loss from care. Increased HIV testing, linkage to care, and retention in care can avert additional deaths and achieve nearly 80% ART coverage with optimal policy improvements. CONCLUSIONS: In resource-limited settings, continued improvements in HIV treatment access will save lives. Efforts to efficiently expand ART access should remain a global priority.
Authors: D W Fitzgerald; P Severe; P Joseph; L R Mellon; E Noel; W D Johnson; J W Pape Journal: J Acquir Immune Defic Syndr Date: 2001-11-01 Impact factor: 3.731
Authors: Uwe Siebert; Oguzhan Alagoz; Ahmed M Bayoumi; Beate Jahn; Douglas K Owens; David J Cohen; Karen M Kuntz Journal: Med Decis Making Date: 2012 Sep-Oct Impact factor: 2.583
Authors: Edward J Mills; Celestin Bakanda; Josephine Birungi; Keith Chan; Nathan Ford; Curtis L Cooper; Jean B Nachega; Mark Dybul; Robert S Hogg Journal: Ann Intern Med Date: 2011-07-18 Impact factor: 25.391
Authors: Myron S Cohen; Ying Q Chen; Marybeth McCauley; Theresa Gamble; Mina C Hosseinipour; Nagalingeswaran Kumarasamy; James G Hakim; Johnstone Kumwenda; Beatriz Grinsztejn; Jose H S Pilotto; Sheela V Godbole; Sanjay Mehendale; Suwat Chariyalertsak; Breno R Santos; Kenneth H Mayer; Irving F Hoffman; Susan H Eshleman; Estelle Piwowar-Manning; Lei Wang; Joseph Makhema; Lisa A Mills; Guy de Bruyn; Ian Sanne; Joseph Eron; Joel Gallant; Diane Havlir; Susan Swindells; Heather Ribaudo; Vanessa Elharrar; David Burns; Taha E Taha; Karin Nielsen-Saines; David Celentano; Max Essex; Thomas R Fleming Journal: N Engl J Med Date: 2011-07-18 Impact factor: 91.245
Authors: Stephen R Cole; Miguel A Hernán; James M Robins; Kathryn Anastos; Joan Chmiel; Roger Detels; Carolyn Ervin; Joseph Feldman; Ruth Greenblatt; Lawrence Kingsley; Shenghan Lai; Mary Young; Mardge Cohen; Alvaro Muñoz Journal: Am J Epidemiol Date: 2003-10-01 Impact factor: 4.897
Authors: Macarthur Charles; Paul D Leger; Patrice Severe; Colette Guiteau; Alexandra Apollon; Roy M Gulick; Warren D Johnson; Jean W Pape; Daniel W Fitzgerald Journal: J Int AIDS Soc Date: 2012-06-14 Impact factor: 5.396
Authors: Monica Malta; Cosme M F P da Silva; Monica Mf Magnanini; Andrea L Wirtz; André R S Perissé; Chris Beyrer; Steffanie A Strathdee; Francisco I Bastos Journal: BMC Public Health Date: 2015-03-07 Impact factor: 3.295
Authors: John A Naslund; Jodie Dionne-Odom; Cléonas Junior Destiné; Kristen M Jogerst; Redouin Renold Sénécharles; Michelande Jean Louis; Jasmin Desir; Yvette Néptune Ledan; Jude Ronald Beauséjour; Roland Charles; Alice Werbel; Elizabeth A Talbot; Patrice Joseph; Jean William Pape; Peter F Wright Journal: AIDS Res Treat Date: 2014-12-07
Authors: Marcel Yotebieng; Ellen Brazier; Diane Addison; April D Kimmel; Morna Cornell; Olivia Keiser; Angela M Parcesepe; Amobi Onovo; Kathryn E Lancaster; Barbara Castelnuovo; Pamela M Murnane; Craig R Cohen; Rachel C Vreeman; Mary-Ann Davies; Stephany N Duda; Constantin T Yiannoutsos; Rose S Bono; Robert Agler; Charlotte Bernard; Jennifer L Syvertsen; Jean d'Amour Sinayobye; Radhika Wikramanayake; Annette H Sohn; Per M von Groote; Gilles Wandeler; Valeriane Leroy; Carolyn F Williams; Kara Wools-Kaloustian; Denis Nash Journal: J Int AIDS Soc Date: 2019-01 Impact factor: 5.396